PubMed Health⌕ Search

Biomedical subjects

P J Bartelloni

Publications and source records attributed to P J Bartelloni.

At least 19 recordsLinked to original sources
PubMed1976

Clinical and serologic responses of volunteers infected with phlebotomus fever virus (Sicilian type).

Twenty volunteers were inoculated with various doses of human serum containing Phlebotomus fever virus (Sicilian type) to determine their clinical and serologic responses as well as the human infectious dose50 of the virus. All infected subjects developed fever which varied in duration from 6 to 74 hours. The most common symptoms during sandfly fever were headache, anorexia, myalgia, photophobia, low back and retro-orbital pain. Infected individuals developed a marked leukopenia characterized by an initial lymphopenia followed by protracted neutropenia. Little complement fixing antibody was detected in convalescent sera but most subjects developed significant rises in hemagglutination inhibiting antibodies. All infected subjects developed specific neutralizing antibodies with titers ranging from 1:40 to 1:2,560. Of the three serologic tests performed, the plaque reduction neutralization method appears to be the most sensitive test for detecting antibodies to Phlebotomus fever viruses.

Adult↗
PubMed1975

Detection of a leukocytic endogenous mediator-like mediator of serum amino acid and zinc depression during various infectious illnesses.

Serum samples from patients with many different kinds of infection were shown to contain a substance characteristic of leukocytic endogenous mediator. Generalized bacterial infections produced more leukocytic endogenous mediator than did localized ones; viral infections produced very little. In typhoid fever, mediator concentrations increased before the onset of illness.

Abscess↗
PubMed1972

Enteric immunization with live adenovirus type 21 vaccine. I. Tests for safety, infectivity, immunogenicity, and potency in volunteers.

Studies were undertaken in volunteers to determine whether living adenovirus type 21 (ADV-21) vaccine could be safely administered orally to susceptible young adults. In the first study, ten volunteers were fed 10(6.4) tissue culture infectious dose(50) (TCID(50)) of ADV-21 vaccine virus, and five received placebo tablets. Nine of ten infected volunteers shed ADV-21 in stools (mean duration, 10.1 days; range, 4 to 17 days). No pharyngeal excretion of ADV-21 was observed in any of these volunteers. Each of the nine developed type-specific neutralizing (N) antibodies to ADV-21. No evidence for person-to-person transmission of vaccine was observed. In a second study, volunteers were immunized with ADV-21 vaccines containing 10(6.8), 10(4.6), and 10(2.4) TCID(50). ADV-21 N antibody responses were detected in nine of eleven who received the highest dose, six of twelve who received the middle dose, and two of twelve who were fed the lowest dose. None of twelve susceptible volunteers receiving the placebo capsule developed ADV-21 N antibodies postimmunization. This study established that the human infectious dose(50) for these lots of ADV-21 vaccine was approximately 10(4.6) TCID(50) and that the dose response to ADV-21 vaccine was lower than those previously reported for live ADV-4 and ADV-7 enteric vaccines.

Adenoviridae↗